These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 19783581)
1. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. Rose J; Hawthorn RL; Watts B; Singer ME BMJ; 2009 Sep; 339():b3653. PubMed ID: 19783581 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France. Standaert B; Parez N; Tehard B; Colin X; Detournay B Appl Health Econ Health Policy; 2008; 6(4):199-216. PubMed ID: 19382820 [TBL] [Abstract][Full Text] [Related]
3. Health impact and cost-effectiveness of a domestically-produced rotavirus vaccine in India: A model based analysis. Rose J; Homa L; Meropol SB; Debanne SM; Bielefeld R; Hoyen C; Singer ME PLoS One; 2017; 12(11):e0187446. PubMed ID: 29099848 [TBL] [Abstract][Full Text] [Related]
4. Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries. Plosker GL Pharmacoeconomics; 2011 May; 29(5):439-54. PubMed ID: 21504245 [TBL] [Abstract][Full Text] [Related]
5. Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries. Plosker GL Pharmacoeconomics; 2011 Nov; 29(11):989-1009. PubMed ID: 21988293 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model. Patel HD; Roberts ET; Constenla DO Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study. Lee H; Park SY; Clark A; Debellut F; Pecenka C; Kim DS; Kim HM; Kim JH; Cho H; Kim AY; Lee M; Jung SY; Seong BL; Kang HY Vaccine; 2019 Aug; 37(35):4987-4995. PubMed ID: 31326252 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan. Itzler RF; Chen PY; Lac C; El Khoury AC; Cook JR J Med Econ; 2011; 14(6):748-58. PubMed ID: 21919673 [TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in developed countries. Plosker GL Drugs R D; 2012 Dec; 12(4):239-44. PubMed ID: 23017130 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of childhood rotavirus vaccination in Germany. Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052 [TBL] [Abstract][Full Text] [Related]
12. Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study. Debellut F; Clark A; Pecenka C; Tate J; Baral R; Sanderson C; Parashar U; Kallen L; Atherly D Lancet Glob Health; 2019 Dec; 7(12):e1664-e1674. PubMed ID: 31708147 [TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in the prevention of rotavirus gastroenteritis in developing countries. Plosker GL Paediatr Drugs; 2012 Dec; 14(6):429-33. PubMed ID: 23013458 [TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of a pentavalent rotavirus vaccine in Oman. Al Awaidy ST; Gebremeskel BG; Al Obeidani I; Al Baqlani S; Haddadin W; O'Brien MA BMC Infect Dis; 2014 Jun; 14():334. PubMed ID: 24941946 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option. Cui S; Tobe RG; Mo X; Liu X; Xu L; Li S BMC Infect Dis; 2016 Nov; 16(1):677. PubMed ID: 27846803 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Rotavirus vaccination in Vietnam. Kim SY; Goldie SJ; Salomon JA BMC Public Health; 2009 Jan; 9():29. PubMed ID: 19159483 [TBL] [Abstract][Full Text] [Related]
18. Projected impact, cost-effectiveness, and budget implications of rotavirus vaccination in Mongolia. Lusvan ME; Debellut F; Clark A; Demberelsuren S; Otgonbayar D; Batjargal T; Purevsuren S; Groman D; Tate J; Pecenka C Vaccine; 2019 Feb; 37(6):798-807. PubMed ID: 30639458 [TBL] [Abstract][Full Text] [Related]
19. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Rheingans RD; Constenla D; Antil L; Innis BL; Breuer T Rev Panam Salud Publica; 2007 Apr; 21(4):205-16. PubMed ID: 17612464 [TBL] [Abstract][Full Text] [Related]
20. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy]. Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]